24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT07325240
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution — DRUG
    Subjects will receive netarsudil-latanoprost fixed combination ophthalmic solution 0.02%/0.005% in one eye and compare it to latanoprost 0.005% in the contralateral eye
  • Latanoprost 0.005% Ophthalmic Solution — DRUG
    latanoprost 0.005% solution will be applied in the contralateral eye, once daily, QD (PM) for 14 days

Study Details

The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).

Key Dates

Start date
Nov 21, 2025
Status verified
Apr 2026
Primary completion
Jul 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: netarsudil-latanoprost arm
  • Active Comparator: latanoprost arm

Primary Outcome Measure

Change in mean Intraocular Pressure (IOP) [ Time Frame: Change in mean IOP after 2 weeks of treatment with Latanoprost compared to baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905
Bridgette Halder
507-422-2780
Arthur J Sit, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By condition
Glaucoma
By specialty
Ophthalmology
By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies